These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 26592763)

  • 1. Assessment of Clostridium difficile Burden in Patients Over Time With First Episode Infection Following Fidaxomicin or Vancomycin.
    Housman ST; Thabit AK; Kuti JL; Quintiliani R; Nicolau DP
    Infect Control Hosp Epidemiol; 2016 Feb; 37(2):215-8. PubMed ID: 26592763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fidaxomicin versus vancomycin for Clostridium difficile infection.
    Louie TJ; Miller MA; Mullane KM; Weiss K; Lentnek A; Golan Y; Gorbach S; Sears P; Shue YK;
    N Engl J Med; 2011 Feb; 364(5):422-31. PubMed ID: 21288078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial.
    Cornely OA; Crook DW; Esposito R; Poirier A; Somero MS; Weiss K; Sears P; Gorbach S;
    Lancet Infect Dis; 2012 Apr; 12(4):281-9. PubMed ID: 22321770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobial activity of LFF571 and three treatment agents against Clostridium difficile isolates collected for a pan-European survey in 2008: clinical and therapeutic implications.
    Debast SB; Bauer MP; Sanders IM; Wilcox MH; Kuijper EJ;
    J Antimicrob Chemother; 2013 Jun; 68(6):1305-11. PubMed ID: 23420839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resolution of Clostridium difficile-associated diarrhea in patients with cancer treated with fidaxomicin or vancomycin.
    Cornely OA; Miller MA; Fantin B; Mullane K; Kean Y; Gorbach S
    J Clin Oncol; 2013 Jul; 31(19):2493-9. PubMed ID: 23715579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pilot study to assess bacterial and toxin reduction in patients with Clostridium difficile infection given fidaxomicin or vancomycin.
    Thabit AK; Alam MJ; Khaleduzzaman M; Garey KW; Nicolau DP
    Ann Clin Microbiol Antimicrob; 2016 Apr; 15():22. PubMed ID: 27071986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro selection, via serial passage, of Clostridium difficile mutants with reduced susceptibility to fidaxomicin or vancomycin.
    Leeds JA; Sachdeva M; Mullin S; Barnes SW; Ruzin A
    J Antimicrob Chemother; 2014 Jan; 69(1):41-4. PubMed ID: 23887866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. U.S.-Based National Sentinel Surveillance Study for the Epidemiology of Clostridium difficile-Associated Diarrheal Isolates and Their Susceptibility to Fidaxomicin.
    Snydman DR; McDermott LA; Jacobus NV; Thorpe C; Stone S; Jenkins SG; Goldstein EJ; Patel R; Forbes BA; Mirrett S; Johnson S; Gerding DN
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6437-43. PubMed ID: 26239985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fidaxomicin: a new macrocyclic, RNA polymerase-inhibiting antibiotic for the treatment of Clostridium difficile infections.
    Poxton IR
    Future Microbiol; 2010 Apr; 5(4):539-48. PubMed ID: 20353295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the in vitro antibacterial activity of Ramizol, fidaxomicin, vancomycin, and metronidazole against 100 clinical isolates of Clostridium difficile by broth microdilution.
    Wolfe C; Pagano P; Pillar CM; Shinabarger DL; Boulos RA
    Diagn Microbiol Infect Dis; 2018 Nov; 92(3):250-252. PubMed ID: 30042035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in the treatment of Clostridium difficile with fidaxomicin: a narrow spectrum antibiotic.
    Sears P; Ichikawa Y; Ruiz N; Gorbach S
    Ann N Y Acad Sci; 2013 Jul; 1291():33-41. PubMed ID: 23672600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Fidaxomicin with C. difficile Spores: Effects of Persistence on Subsequent Spore Recovery, Outgrowth and Toxin Production.
    Chilton CH; Crowther GS; Ashwin H; Longshaw CM; Wilcox MH
    PLoS One; 2016; 11(8):e0161200. PubMed ID: 27556739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Antimicrobial therapy of Clostridium difficile infection. Systematic review and meta-analysis of the scientific evidence].
    Brodszky V; Gulácsi L; Ludwig E; Prinz G; Banai J; Reményi P; Strbák B; Kertész A; Kopcsóné Németh I; Zsoldiné Urbán E; Baji P; Péntek M
    Orv Hetil; 2013 Jun; 154(23):890-9. PubMed ID: 23728312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fidaxomicin "chaser" regimen following vancomycin for patients with multiple Clostridium difficile recurrences.
    Johnson S; Gerding DN
    Clin Infect Dis; 2013 Jan; 56(2):309-10. PubMed ID: 23024296
    [No Abstract]   [Full Text] [Related]  

  • 15. Cadazolid Does Not Promote Intestinal Colonization of Vancomycin-Resistant Enterococci in Mice.
    Seiler P; Enderlin-Paput M; Pfaff P; Weiss M; Ritz D; Clozel M; Locher HH
    Antimicrob Agents Chemother; 2016 Jan; 60(1):628-31. PubMed ID: 26503650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is fidaxomicin the drug of choice for treating Clostridium difficile-associated diarrhea in patients with cancer?
    Green MR; Acharya UH; Yeager AM
    J Clin Oncol; 2013 Dec; 31(34):4376-8. PubMed ID: 24166524
    [No Abstract]   [Full Text] [Related]  

  • 17. Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile infections.
    Lancaster JW; Matthews SJ
    Clin Ther; 2012 Jan; 34(1):1-13. PubMed ID: 22284993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial.
    Guery B; Menichetti F; Anttila VJ; Adomakoh N; Aguado JM; Bisnauthsing K; Georgopali A; Goldenberg SD; Karas A; Kazeem G; Longshaw C; Palacios-Fabrega JA; Cornely OA; Vehreschild MJGT;
    Lancet Infect Dis; 2018 Mar; 18(3):296-307. PubMed ID: 29273269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of fidaxomicin for treatment of relapsed Clostridium difficile infections in patients with cancer.
    Esmaily-Fard A; Tverdek FP; Crowther DM; Ghantoji SS; Adachi JA; Chemaly RF
    Pharmacotherapy; 2014 Nov; 34(11):1220-5. PubMed ID: 25164587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin.
    Al-Nassir WN; Sethi AK; Nerandzic MM; Bobulsky GS; Jump RL; Donskey CJ
    Clin Infect Dis; 2008 Jul; 47(1):56-62. PubMed ID: 18491964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.